Apogee Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Apogee Therapeutics, Inc. Common Stock (APGE) has an Asset Resilience Ratio of 47.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Apogee Therapeutics, Inc. Common Stock to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Apogee Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Apogee Therapeutics, Inc. Common Stock (APGE) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Apogee Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Apogee Therapeutics, Inc. Common Stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $608.09 Million | 47.01% |
| Total Liquid Assets | $608.09 Million | 47.01% |
Asset Resilience Insights
- Very High Liquidity: Apogee Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 47.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Apogee Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Apogee Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Apogee Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 63.88% | $598.64 Million | $937.13 Million | +13.63pp |
| 2024-12-31 | 50.25% | $378.86 Million | $753.95 Million | -18.79pp |
| 2023-12-31 | 69.04% | $277.14 Million | $401.40 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $152.06 Million | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more